Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA to relax product modification regulations?

This article was originally published in Clinica

Executive Summary

US device manufacturers may no longer have to file a 510(k) when if they make substantial products modifications. A guidance document to be issued to FDA staff by the Center for Devices and Radiological Health urges leniency in dealing with companies already complying with the preproduction design controls required as part of the agency's new good manufacturing practices rule, says center director Bruce Burlington. Although the design portion of that rule does not come into effect until 1998, many companies will begin adopting it next year. With the design documentation available, a revised 510(k) submission would be redundant, claims the agency.

You may also be interested in...



Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT089840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel